Modified Citrus Pectin Shows Potential in Relapsed Prostate Cancer Patients, Study Suggests

Modified Citrus Pectin Shows Potential in Relapsed Prostate Cancer Patients, Study Suggests
Treament with modified citrus pectin (MCP), a nutritional supplement, led to promising results in men with recurrent prostate cancer, according to preliminary results from a Phase 2b trial. The study with the results, "Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study," was published in the Journal of Clinical Oncology in conjunction with the 2017 AS
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *